5 Key Takeaways

• 1

  OCS-01, a topical eye drop for diabetic macular edema, showed significant vision gains and retinal thickness reductions in the DIAMOND stage 1 trial.

• 2

  Patients using OCS-01 experienced a mean best-corrected visual acuity improvement of 7.2 letters at week 6, compared to 3.1 letters in the placebo group.

• 3

  Statistically significant reductions in central subfield thickness were observed with OCS-01, with a difference of 69.1 µm at week 6 and 45 µm at week 12.

• 4

  A greater proportion of patients on OCS-01 achieved a ≥15-letter BCVA gain by week 12, with 27.4% in the treatment group versus 7.5% in the placebo.

• 5

  Increased intraocular pressure was noted in the OCS-01 group, with 22 cases reported, but IOP typically returned to baseline after treatment cessation.